# Junta clínica — PT-pseudo_d3e975d025e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d3e975d025e6",
  "pid": "PT-pseudo_d3e975d025e6",
  "task": 1,
  "psa": 15.8,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.318,
  "psav": 0.96,
  "psap": 15.4,
  "vol": 49.63,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.84823215,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "69 kg",
    "height": "179 cm",
    "bmi": "21.5",
    "bp": "127/86 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "18 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results."
    },
    {
      "s": "History",
      "t": "First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly."
    }
  ],
  "occupation": "tram driver",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "6 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3e975d025e6
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 15.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.318 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 15.4 ng/mL
  - Prostate volume: 49.63 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84823215 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.

Vitals: weight 69 kg, height 179 cm, BMI 21.5, BP 127/86 mmHg, HR 72 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results.

History: First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly.

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.81
  uncertainty  +/- 0.08 (95% CI 0.65-0.98); among patients it cannot tell apart the outcome was 0.69 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that adding perilesional sampling to targeted biopsy could mitigate the drawbacks of the MRI pathway by maintaining good detection of csPCa while decreasing the overdiagnosis of insignificant cancer.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the specific threshold of PI-RADS 3 mentioned in the guideline. It also does not incorporate the guideline's nuance regarding the benefit of adding perilesional sampling to targeted biopsy.

WHAT WE STILL NEED
The mpMRI prose - the PI-RADS score of 5 indicates a high-risk lesion, which aligns with the guideline's consideration of lesions $\ge 3$. This suggests a biopsy is indicated based on the imaging finding.
The PSA trend - the PSA velocity of $0.96 \text{ ng/mL/yr}$ indicates a rising trend, which is a variable the guideline makes decisive regarding the need for further investigation.
The previous notes - the prior biopsy status is "None," which is a factor the guideline makes decisive regarding the need for further investigation.
The laboratory results - the PSA density of $0.318 \text{ ng/mL/cc}$ is a variable the guideline makes decisive regarding the need for further investigation.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the high PI-RADS score, rising PSA velocity, and prior lack of biopsy meet the EAU criteria for proceeding with a biopsy.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion size and zone, to confirm the PI-RADS 5 finding.
  psa_trend (get_psa_trend) -> Determine the serial PSA values to confirm the PSA velocity trend.
  previous_notes (get_previous_notes) -> Determine the prior biopsy status to assess the management context.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the radiology report state regarding the lesion size and zone for the PI-RADS 5 finding?
  Q2. What does the PSA trend show beyond the headline value of 15.8 ng/mL?
  Q3. What does the previous notes section state regarding the prior biopsy status?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The radiology report states the PI-RADS 5 lesion is in the left peripheral zone, spanning the base through the mid-gland, measuring approximately 18 mm.
psa_trend
The PSA trend shows serial values: 3.9 ng/mL on Jan 2023, 5.5 ng/mL on Jul 2023, 7.8 ng/mL on Jan 2024, 11.1 ng/mL on Jul 2024, and 15.8 ng/mL on Jan 2025.
previous_notes
The previous notes section states the prior biopsy status was "None".

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them in the plan, and the key variables for the decision were covered by the other requested documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose confirms a PI-RADS 5 lesion measuring approximately 18 mm.
The PSA trend shows a rising trend, with the most recent value being 15.8 ng/mL.
The previous notes confirm the prior biopsy status was "None".
AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The imaging finding, rising PSA trend, and prior lack of biopsy strongly support proceeding with a biopsy according to the EAU guideline considerations.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar successfully answered all three moderator questions by opening the `radiology_report`, `psa_trend`, and `previous_notes`. The information retrieved directly addresses the specific details requested for each open question.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY, as the findings—PI-RADS 5 lesion, rising PSA trend, and prior biopsy status of "None"—all support the need for further investigation.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology report state regarding the lesion size and zone for the PI-RADS 5 finding? Answered by the registrar via the `radiology_report`: The PI-RADS 5 lesion is in the left peripheral zone, spanning the base through the mid-gland, measuring approximately 18 mm.
Q2. What does the PSA trend show beyond the headline value of 15.8 ng/mL? Answered by the registrar via the `psa_trend`: The trend shows serial values: 3.9 ng/mL on Jan 2023, 5.5 ng/mL on Jul 2023, 7.8 ng/mL on Jan 2024, 11.1 ng/mL on Jul 2024, and 15.8 ng/mL on Jan 2025.
Q3. What does the previous notes section state regarding the prior biopsy status? Answered by the registrar via the `previous_notes`: The prior biopsy status was "None".

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score ($\ge 3$) because it indicates a high-risk lesion, the PSA velocity ($0.96 \text{ ng/mL/yr}$) because it shows a rising trend, and the prior biopsy status ("None") because it indicates a lack of prior definitive diagnosis. The room has leaned on the imaging finding and the trend, which the guideline supports.

MY SUGGESTION TO THE CHAIR
Based on the guideline considerations and the evidence provided, a biopsy is indicated to proceed with further investigation.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by the PI-RADS 5 finding, which is decisive, combined with a rising PSA trend and a prior biopsy status of 'None'. The EAU guideline considerations, supported by the retrieved data, indicate that these factors mandate further investigation. The room converged on proceeding with a biopsy based on the high-risk imaging and clinical trajectory.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, pirads=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes
